Significant advances have been made in chimeric antigen receptor T (CAR-T)-cell therapy for the treatment of recurrent or refractory B-cell hematologic malignancies. However, CAR-T-cell therapy has not yet achieved comparable success in the management of aggressive T-cell malignancies. This article reviews the challenges of CAR-T-cell therapy in treating T-cell malignancies and summarizes the progress of preclinical and clinical studies in this area. We present an analysis of clinical trials of CAR-T-cell therapies for the treatment of T-cell malignancies grouped by target antigen classification. Moreover, this review focuses on the major challenges encountered by CAR-T-cell therapies, including the nonspecific killing due to T-cell target antigen sharing and contamination with cell products during preparation. This review discusses strategies to overcome these challenges, presenting novel therapeutic approaches that could enhance the efficacy and applicability of CAR-T-cell therapy in the treatment of T-cell malignancies. These ideas and strategies provide important information for future studies to promote the further development and application of CAR-T-cell therapy in this field.

中文翻译：

---

CAR-T 细胞治疗 T 细胞恶性肿瘤的研究进展


嵌合抗原受体 T （CAR-T） 细胞疗法治疗复发性或难治性 B 细胞血液系统恶性肿瘤已取得重大进展。然而，CAR-T 细胞疗法在治疗侵袭性 T 细胞恶性肿瘤方面尚未取得可比的成功。本文综述了 CAR-T 细胞疗法治疗 T 细胞恶性肿瘤的挑战，并总结了该领域的临床前和临床研究进展。我们分析了 CAR-T 细胞疗法治疗 T 细胞恶性肿瘤的临床试验，按靶抗原分类分组。此外，本文重点介绍了 CAR-T 细胞疗法遇到的主要挑战，包括 T 细胞靶抗原共享和制备过程中细胞产物污染导致的非特异性杀伤。本综述讨论了克服这些挑战的策略，提出了可以提高 CAR-T 细胞疗法治疗 T 细胞恶性肿瘤的疗效和适用性的新型治疗方法。这些思路和策略为未来的研究提供了重要信息，以促进 CAR-T 细胞疗法在该领域的进一步发展和应用。